Clinical Trial Update: TCb vs EC-T in High Risk ER+/HER2- Breast Cancer [Phase 3]

View source ↗

Summary

Phase 3 clinical trial update comparing TCb versus EC-T in high-risk ER+/HER2- breast cancer; currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer
• Hormone Receptor-positive Breast Cancer

Drugs mentioned

• EC-T
• TCb

Snippet

Sponsor: Fudan University | Conditions: Hormone Receptor Positive HER-2 Negative Breast Cancer | Phase 3 | Status: RECRUITING